Get started
Author

Yuki Takumoto

Observed names: Takumoto, Yuki, Y Takumoto, Y. Takumoto
ORCID: 0000-0001-9191-3494
Observed ORCID: 0000-0001-9191-3494
OpenAlex ID: A5086507106
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis
2022 · Yuki Takumoto, Yuriko Sasahara, et al. · JAMA Network Open · 17
PDF
Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
2022 · Yuki Takumoto, Yuriko Sasahara, et al. · Health Economics Review · 10
PDF
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study
2023 · Yuki Takumoto, Ryotaro Shibahara, et al. · Cancer Medicine · 5
PDF
Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial
2022 · Yuki Takumoto, Takeru Shiroiwa, et al. · Clinical Drug Investigation · 3
PDF
Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors
2025 · Naruto Taira, Naomi Kiyota, et al. · Japanese Journal of Clinical Oncology · 2
Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians
2024 · Yuriko Sasahara, Yuki Takumoto, et al. · Frontiers in Health Services · 2
Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
2023 · Yuki Takumoto, Yuriko Sasahara, et al. · Health Economics Review · 2
PDF
Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data
2025 · Akira Shinohara, Yuki Takumoto, et al. · Scientific Reports · 1
PDF
Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan
2025 · Yuriko Sasahara, Yuki Takumoto, et al. · Cancer Medicine
PDF
Electronic Patient‐Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second‐Line Chemotherapy: A Multicenter Observational Study
2025 · Yuki Takumoto, Akihiro Ohba, et al. · Cancer Medicine
PDF
EPH140 Targeted Literature Review of the Clinical, Social, and Economic Burdens of Schizophrenia in Japan
2024 · F Ono, Y Takumoto, et al. · Value in Health
PDF
MSR177 Health-Related Quality-of-Life (HRQoL) Assessment for Japanese Cognitive Impairment Associated With Schizophrenia (CIAS)
2024 · S Noto, Y Takumoto, et al. · Value in Health
切除不能膵がんに対する癌化学療法の費用効果分析
2023 · 宅本, 悠希, Takumoto, Yuki · Institutional Repositories DataBase (IRDB)
PDF
Electronic patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy: A multicenter prospective observational study.
2023 · Akihiro Ohba, Yuki Takumoto, et al. · Journal of Clinical Oncology
PCR43 Comparison of Face-to-Face and Online Surveys of Measuring Utility for Metastatic Pancreatic Cancer in Japan Using Composite Time Trade-Off
2022 · Y Takumoto, T Murata, et al. · Value in Health
POSA381 Health State Utility Values for Metastatic Pancreatic Cancer in Japan, Based on the Vignette-Based Approach
2022 · Y Takumoto, H Narimatsu, et al. · Value in Health
Pcn248 Cost-utility Analysis of First-line Therapy for Advanced and Metastatic Pancreatic Cancer in Japan.
2019 · Y. Takumoto, T. Kudo, et al. · Value in Health
PDF
Critical issues influencing cost-effectiveness analyses of pneumococcal vaccine strategy for elderly in japan
2016 · Y Takumoto, M Akazawa, et al. · Value in Health
Works count: 18
Citation count: 42
H-index: 3
I10-index: 2
Year
Topic
Type